Xiang-Qun (Sean) Xie
University of Pittsburgh
Xiang-Qun (Sean) Xie, MD, PhD, EMBA is an Associate Dean and Professor of the School of Pharmacy, and a PI of an integrated Medicinal Chemistry Biology Laboratory of Compu Group, Bio Group and Chem Group at the University of Pittsburgh. He serves as a FDA Science Board Member. He is a Director/PI of NIDA-funded National Center of Excellence for CDAR (www.CDARCenter.org). He serves as an Editorial Advisory Board member for AAPS Journal. He was a Charter Member of NIH BPNS Study Section, and an ad hoc expert reviewer for UK MRC foundation; the Wellcome Trust Fund; the Netherland Organization for Scientific Research Council; the Austrian Science Fund (FWF); and the Chinese Natural Science Foundation. Xie’s team is known for its pioneering research on development of “Big Data to Knowledge” GPU-accelerated diseases-specific chemo genomics knowledge bases and machine-/deep-learning algorithm Target Hunter platform for target identification and system pharmacology translational research. His recent published work (www.CBLigand.org/CCGS) includes Alzheimer’s disease knowledgebase (2014 ACS JCIM cover page story); innovative GPU-accelerated cloud computing Target Hunter program for drug target identification (2013 AAPS special theme issue); the first discovered/patented INK4C-targeting small-molecule modulators for hematopoietic stem cell expansion (Nature Comm 2015; Sci Reports, 2015); the first discovered/patented p62ZZ chemical inhibitors for multiple myeloma (Nature Leukemia 2016, Nature Comm 2017); the first on Nature Scientific Report (2016) about cardiovascular disease-specific chemo genomics knowledgebase-guided target identification and drug synergy mechanism study of a combination of herbal medications "Sini Decoction" (四逆汤); and also reported/patented novel ligands specific to cannabinoid CB2 receptor for osteoporosis and cancers (JMC, PNAS). He was also a recipient of 2014 AAPS Award for Outstanding Research Achievements. Sean Xie received his MD in Pharmacy 1982 from the 2nd Military Medical University, China; his PhD in Medicinal Chemistry 1993 from the School of Pharmacy, University of Connecticut, USA; and Executive MBA degree 2003.
integrated Medicinal Chemistry Biology, recent published work includes Alzheimer’s disease knowledge base, and chemo genomics.